Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma

Biochemical and Biophysical Research Communications

Volumn 365, Issue 3, 2008, Pages 568-574

  Kikuchi, Ken ^a   Tsuchiya, Kunihiko ^a   Otabe, Osamu ^a   Gotoh, Takahiro ^a   Tamura, Shinichi ^a   Katsumi, Yoshiki ^a   Yagyu, Shigeki ^a   Tsubai Shimizu, Satoko ^a   Miyachi, Mitsuru ^a   Iehara, Tomoko ^a   Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cell cycle progression; MET; Motility; Muscle differentiation; Myogenin; PAX3 FKHR; Rhabdomyosarcoma; siRNA

Indexed keywords

MYOSIN HEAVY CHAIN;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC DIFFERENCE; HUMAN; HUMAN CELL; MUSCLE DEVELOPMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR CELL;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MUSCLE DEVELOPMENT; MUSCLE NEOPLASMS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; RHABDOMYOSARCOMA, ALVEOLAR; RNA, SMALL INTERFERING;

EID: 36549038528     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.11.017     Document Type: Article

References (22)

1. Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher III F.J., Emanuel B.S., Rovera G., and Barr F.G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5 (1993) 230-235
2. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., and Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20 (2002) 2672-2679
3. Epstein J.A., Lam P., Jepeal L., Maas R.S., and Shapiro D.N. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J. Biol. Chem. 270 (1995) 11719-11722
4. Maroto M., Reshef R., Munsterberg A.E., Koester S., Goulding M., and Lassar A.B. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89 (1997) 139-148
5. Fredericks W.J., Galili N., Mukhopadhyay S., Rovera G., Bennicelli J., Barr F.G., and Rauscher III F.J. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15 (1995) 1522-1535
6. Scheidler S., Fredericks W.J., Rauscher III F.J., Barr G.F., and Vogt P.K. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc. Natl. Acad. Sci. USA 93 (1996) 9805-9809
7. Wang W., Slevin M., Kumar S., and Kumar P. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int. J. Oncol. 27 (2005) 1087-1096
8. Anderson J., Ramsay A., Gould S., and Pritchard-Jones K. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Am. J. Pathol. 159 (2001) 1089-1096
9. Bernasconi M., Remppis A., Fredericks W.J., Rauscher III F.J., and Schafer B.W. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl. Acad. Sci. USA 93 (1996) 13164-13169
10. E. Ebauer, M. Wachtel, F.K. Niggli, B.W. Schafer, Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR, Oncogene 21 (in press).
11. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
12. Tsuchiya K., Hosoi H., Misawa-Furihata A., Houghton P.J., and Sugimoto T. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells. Int. J. Oncol. 31 (2007) 41-47
13. Zhang L., and Wang C. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression. J. Biol. Chem. 278 (2003) 27-36
14. Burgess T.L., Fisher E.F., Ross S.L., Bready J.V., Qian Y.X., A Bayewitch L., Cohen A.M., Herrera C.J., Hu S.S., Kramer T.B., Lott F.D., Martin F.H., Pierce G.F., Simonet L., and Farrell C.L. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92 (1995) 4051-4055
15. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., and Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296 (2002) 1000-1004
16. Ginsberg J.P., Davis R.J., Bennicelli J.L., Nauta L.E., and Barr F.G. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 58 (1998) 3542-3546
17. Jankowski K., Kucia M., Wysoczynski M., Reca R., Zhao D., Trzyna E., Trent J., Peiper S., Zembala M., Ratajczak J., Houghton P., Janowska-Wieczorek A., and Ratajczak M.Z. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 63 (2003) 7926-7935
18. Hosoi H., Sugimoto T., Hayashi Y., Inaba T., Horii Y., Morioka H., Fushiki S., Hamazaki M., and Sawada T. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int. J. Cancer 50 (1992) 977-983
19. Begum S., Emani N., Cheung A., Wilkins O., Der S., and Hamel P.A. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 24 (2005) 1860-1872
20. Davicioni E., Finckenstein F.G., Shahbazian V., Buckley J.D., Triche T.J., and Anderson M.J. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66 (2006) 6936-6946
21. Zhang L., and Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene 26 (2007) 1595-1605
22. Dias P., Chen B., Dilday B., Palmer H., Hosoi H., Singh S., Wu C., Li X., Thompson J., Parham D., Qualman S., and Houghton P. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am. J. Pathol. 156 (2000) 399-408